M. Lewiecki

Review of Treatment Modalities for Postmenopausal Osteoporosis

N. Watts, M. Holick, M. Maricic, 2005, Southern medical journal.

Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study

G. Cutter, M. Danila, K. Saag, 2017, Osteoporosis International.

Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 1: Hip Geometry.

J. Cauley, W. Leslie, J. Shepherd, 2015, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Treatment of osteoporosis with denosumab.

E. Lewiecki, M. Lewiecki, 2010, Maturitas.

International Journal of Women's Health Dovepress Sclerostin Inhibition: a Novel Therapeutic Approach in the Treatment of Osteoporosis

D. Shoback, E. Lewiecki, M. Lewiecki, 2022 .

New and Emerging Therapies for Osteoporosis

J. Reginster, M. Brandi, B. Williams, 2010, Journal of osteoporosis.

Long dosing intervals in the treatment of postmenopausal osteoporosis

E. Michael Lewiecki, M. Lewiecki, 2007 .

Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy

E. Lewiecki, M. Lewiecki, M. Sharifi, 2014, Expert review of clinical pharmacology.

Emerging anabolic agents in the treatment of osteoporosis

E. Lewiecki, C. Lovato, M. Lewiecki, 2017, Expert Opinion on Emerging Drugs.

Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.

T. Keaveny, D. Kopperdahl, M. Kleerekoper, 2014, The Journal of bone and joint surgery. American volume.

Denosumab: an investigational drug for the management of postmenopausal osteoporosis

E. Lewiecki, M. Lewiecki, Michael Lewiecki, 2008, Biologics : targets & therapy.